TALVEY®▼ (talquetamab) Patient Card

Carry this card with you at all times.
SHOW THIS CARD to any healthcare professional involved in your care and if you go to the hospital.

TALVEY® can cause side effects such as Cytokine Release Syndrome (CRS) and neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).[1,2]

Patient's name:

Important Safety Information for Patients

Get medical help straight away if you experience any of the following:

Cytokine Release Syndrome

- Fever
- Lower blood pressure
- Chills
- Difficulty breathing
- Fatigue
- Headache
- Fast heartbeat

Neurologic toxicity, including ICANS

- Feeling confused
- Feeling less alert
- Feeling disoriented
- Feeling sleepy
- Slow or difficulty thinking
- Altered thinking or decreased consciousness
- Confusion
- Difficulty speaking and understanding speech

Important to remember

Stay close to the location where you received your TALVEY® therapy for at least 2 days for daily monitoring after administration of all doses of the step-up dosing schedule.

If you have **any** of the symptoms listed on this card, call your doctor, or seek emergency medical attention right away. **These are not all the possible side effects of TALVEY®. Tell your doctor if you have any side effect that bothers you or does not go away.**

Johnson&Johnson

CP-492264 | Nov 2025

Treating Physician

Treating physician's name:

.....

Treating physician's phone number:

.....

Hospital name and address:

.....

Phone number:

.....

Information for Healthcare Team to fill in

Please give this card to your healthcare team to fill in the information and return to you. Dates of TALVEY® injections (step-up dosing schedule):

Step-up dose 1 .....

Step-up dose 2 .....

Step-up dose 3 .....

Step-up dose 4* .....

Treatment phase‡ .....

*For the biweekly dosing only.
‡For the weekly dosing this is 0.4 mg/kg once every week thereafter.
For the biweekly dosing this is 0.8 mg/kg once every two weeks thereafter.

Important Safety Information for Healthcare Professionals

CRS and neurologic toxicity including ICANS, may occur in patients receiving TALVEY®, and can be fatal or life-threatening. The majority of these events observed following TALVEY® administration were Grade 1 and 2.[1,2]

Assess the patient for signs and symptoms of CRS and ICANS.

If your patient reports any signs or symptoms as referenced on this card, please contact the patient's treating physician immediately for further information.

See Summary of Product Characteristics for full details.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the national reporting system: Yellow Card Scheme (https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store). Alternatively you can call 0800 731 6789 for free, Monday to Friday between 9:00am and 5:00pm. Any adverse reactions to TALVEY® should be reported to Johnson & Johnson via email (dsafety@its.jnj.com) or by telephone (01494 567447).

1. TALVEY® Solution for injection UKGB Summary of Product Characteristics, available from www.medicines.org.uk (last accessed November 2024).
2. TALVEY® Solution for injection UKNI Summary of Product Characteristics, available from www.emcmedicines.com/en-GB/northernireland/ (last accessed November 2024).

Johnson&Johnson

CP-492264 | Nov 2025